메뉴 건너뛰기
Clinical Cancer Research
Volumn 19, Issue 16, 2013, Pages 4541-4542
Oncolytic virotherapy trials-Letter
Author keywords

[No Author keywords available]
Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS;
EID: 84882987166     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1471     Document Type: Letter
Times cited : (16)
References (6)
  • 1
    • 84878041823 scopus 로고    scopus 로고
    • Oncolytic virotherapy needs trials, not access programs
    • Harrington KJ. Oncolytic virotherapy needs trials, not access programs. Clin Cancer Res 2013;19:2595-7.
    • (2013) Clin Cancer Res , vol.19 , pp. 2595-2597
    • Harrington, K.J.1
  • 2
    • 84878074018 scopus 로고    scopus 로고
    • Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus
    • Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013;19: 2734-44.
    • (2013) Clin Cancer Res , vol.19 , pp. 2734-2744
    • Kanerva, A.1    Nokisalmi, P.2    Diaconu, I.3    Koski, A.4    Cerullo, V.5    Liikanen, I.6
  • 3
    • 80052420081 scopus 로고    scopus 로고
    • Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus
    • Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011;19:1737-46.
    • (2011) Mol Ther , vol.19 , pp. 1737-1746
    • Cerullo, V.1    Diaconu, I.2    Kangasniemi, L.3    Rajecki, M.4    Escutenaire, S.5    Koski, A.6
  • 4
    • 44849121355 scopus 로고    scopus 로고
    • Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies
    • Sarkioja M, Pesonen S, Raki M, Hakkarainen T, Salo J, Ahonen MT, et al. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther 2008;15:921-9.
    • (2008) Gene Ther , vol.15 , pp. 921-929
    • Sarkioja, M.1    Pesonen, S.2    Raki, M.3    Hakkarainen, T.4    Salo, J.5    Ahonen, M.T.6
  • 5
    • 79958140936 scopus 로고    scopus 로고
    • Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients
    • Raki M, Sarkioja M, Escutenaire S, Kangasniemi L, Haavisto E, Kanerva A, et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 2011;13:253-61.
    • (2011) J Gene Med , vol.13 , pp. 253-261
    • Raki, M.1    Sarkioja, M.2    Escutenaire, S.3    Kangasniemi, L.4    Haavisto, E.5    Kanerva, A.6
  • 6
    • 84876910443 scopus 로고    scopus 로고
    • The integration of T cell migration, differentiation and function
    • Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol 2013;13:309-20.
    • (2013) Nat Rev Immunol , vol.13 , pp. 309-320
    • Masopust, D.1    Schenkel, J.M.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.